Table 6.
Percentage of different antimicrobial genotypes of MDR GNB isolates
| MDR GNB | Genotypes | No. of isolates (%a) | Significant associationsb | Pearson chi-square |
|---|---|---|---|---|
| Positive (n=58) | tem/shv/aac(6′)-Ib | 2 (3%) | Ciprofloxacin/shv | 0.022 |
| tem/shv/ctx-m/qnrS/aac(6′)-Ib | 3 (5%) | Ciprofloxacin/aac-6′ | 0.023 | |
| tem/shv/ctx-m/qnrB/aac(6′)-Ib | 2 (3%) | Levofloxacin/shv | 0.05 | |
| tem/shv/ctx-m/qnrB/qnrS/aac(6′)-Ib | 2 (3%) | Levofloxacin/aac-6′ | 0.03 | |
| tem/shv/ctx-m/qnrA/qnrS/a aac(6′)Ib | 2 (3%) | Amikacin/tem | 0.026 | |
| tem/shv/qnrS/aac(6′)-Ib | 2 (3%) | Amikacin/shv | 0.008 | |
| tem/ctx-m | 4 (7%) | Amikacin/aac-6′ | 0.031 | |
| tem/aac(6′)-Ib | 2 (3%) | Imipenem/shv | 0.037 | |
| tem/shv/ctx-m/aac(6′)-Ib | 3 (5%) | Imipenem/ctx-m | 0.022 | |
| shv/ctx-m | 3 (5%) | Meropenem/shv | 0.037 | |
| shv | 2 (3%) | Meropenem/ctx-m | 0.004 | |
| shv/aac(6′)-Ib | 2 (3%) | meropenem/aac-6′ | 0.05 | |
| shv/qnrS/aac(6′)-Ib | 3 (5%) | ertapenem/shv | 0.026 | |
| shv/ctx-m/aac(6′)-Ib | 4 (7%) | ertapenem/ctx-m | 0.004 | |
| shv/ctx-m/qnrB/qnrS/aac-6′ | 1 (1.7%) | |||
| ctx-m | 3 (5%) | |||
| ctx-m/aac(6′)-Ib | 6 (10%) | |||
| ctx-m/qnrS | 2 (3%) | |||
| ctx-m/qnrB | 2 (3%) | |||
| ctx-m/qnrB/qnrS/aac(6′)-Ib | 2 (3%) | |||
| qnrS/aac(6′)-Ib | 2 (3%) | |||
| aac(6′)-Ib | 4 (7%) | |||
| Negative (n=12) | – | 12 (17) |
Notes: Genotypes, plasmid-mediated antimicrobial resistance.
a
Percentages were calculated with reference to the number positive MDR GNB.
b
Significant association between antibiotic resistance and PCR detection of the respective gene on plasmids.
Abbreviations: MDR GNB, multidrug-resistant Gram-negative bacteria; PCR, polymerase chain reaction.